7 completed, 3 terminated. 9 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 3 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow CRS-207: new trials by email Literature Review of CRS-207 trials Research Report on CRS-207
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer Tadalafil, Pembrolizumab, Ipilimumab - Pancreatic Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 17 | 2022-08-22 | 2026-04-28 |
| Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer Epacadostat, Pembrolizumab, CRS-207 - Metastatic Pancreatic Adenocarcinoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 41 | 2018-01-31 | 2024-10-08 |
| Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer Cyclophosphamide, Nivolumab, Ipilimumab - Pancreatic Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 61 | 2017-12-14 | 2024-08-07 |
| Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers CRS-207, Pembrolizumab - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Terminated | Aduro Biotech, Inc. | 5 | 2017-08-14 | 2019-04-04 |
| Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) CRS-207, Pembrolizumab - Malignant Pleural Mesothelioma | Phase 2 | Terminated | Aduro Biotech, Inc. | 10 | 2017-05-31 | 2019-04-04 |
| Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer CRS-207, Epacadostat, Pembrolizumab - Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer | Phase 1 / Phase 2 | Terminated | Aduro Biotech, Inc. | 35 | 2016-03-08 | 2019-04-04 |
| GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab CRS-207, nivolumab, GVAX - Previously Treated Metastatic Adenocarcinoma of the Pancreas | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 93 | 2015-01-02 | 2021-04-06 |
| Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma Immunotherapy plus chemotherapy, Immunotherapy with cyclophosphamide plus chemotherapy - Malignant Pleural Mesothelioma | Phase 1 | Completed | Aduro Biotech, Inc. | 60 | 2014-09-03 | 2020-09-30 |
| Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting GVAX Pancreas Vaccine, CRS-207, Chemotherapy - 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer | Phase 2 | Completed | Aduro Biotech, Inc. | 303 | 2014-02-05 | 2018-06-04 |
| Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer GVAX Pancreas, CRS-207, Cyclophosphamide - Metastatic Pancreatic Cancer | Phase 2 | Completed | Aduro Biotech, Inc. | 93 | 2011-09-21 | 2018-05-08 |
Neoplasms (4) · Pancreatic Neoplasms (4) · Adenocarcinoma (2) · Carcinoma (2) · Mesothelioma, Malignant (2) · Adenocarcinoma Of Esophagus (1) · Digestive System Diseases (1) · Esophageal Neoplasms (1) · Gastrointestinal Diseases (1) · Ovarian Neoplasms (1) · Stomach Diseases (1) · Stomach Neoplasms (1)
Aduro Biotech, Inc. (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4)
United States (10) · Canada (2)
Dung Le, MD (2) · Dung Le, M.D. (1) · Dung T Le, MD (1) · Katherine Bever, MD (1) · Raffit Hassan, MD (1)
PMID 29997287, PMID 31126960, PMID 31263030
P01CA247886 (3)